HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases

Journal of Investigative Dermatology

Volumn 113, Issue 5, 1999, Pages 747-751

  Borg von Zepelin, Margarete ^a   Meyer, Ingo ^a   Thomssen, Reiner ^a   Würzner, Reinhard ^b   Sanglard, Dominique ^c   Telenti, Amalio ^c   Monod, Michel ^c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Adherence; Aspartic protease inhibitors; Aspartic proteases; Candida albicans; Human immunodeficiency virus inhibitors; Oropharyngeal candidiasis

Indexed keywords

ANTIRETROVIRUS AGENT; ASPARTIC PROTEINASE; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RECOMBINANT ENZYME; RITONAVIR; SAQUINAVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL ADHESION; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; VERO CELL; YEAST;

EID: 0032728881     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1999.00747.x     Document Type: Article

References (26)

1. Borg M, Rüchel R: Expression of extracellular acid proteinase by proteolytic Candida spp during experimental infection of oral mucosa. Infect Immun 56:626-631, 1988
2. Borg-von Zepelin M, Wagner T: Fluorescence assay for the detection of adherent Candida yeasts to target cells in microtest plates. Mycoses 38:339-347, 1995
3. Borg-von Zepelin M, Beggah S, Boggian K, Sanglard D, Monod M: The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages. Mol Microbiol 28:543-554, 1998
4. Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
5. Cassone A, Adriani D, Tacconelli E, Cauda R, De Bernardis F: HIV protease inhibitors have a direct anti-Candida effect by inhibition of Candida aspartyl proteinase 12th World AIDS Conference, Geneva., Abstract 31211, 1998
6. Cutler JE: Putative virulence factors of Candida albicans. Annu Rev Microbiol 45:187-218, 1991
7. De Bernardis F, Cassone A, Sturtervant J, Calderone R: Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect Immun 63:1887-1892, 1995
8. De Bernardis F, Arancia S, Morelli L, Hube B, Sanglard D, Schäfer W, Cassone A: Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 179:201-208, 1999
9. Diz P, Ocampo A, Iglesias I, Otero I: Lack of ritonavir antifungal effect in vitro. Antimicrob Agents Chermother 43:997, 1999
10. Egger M, Hirschel B, Francioli P, et al: Impact of new retroviral combination therapies in HIV infected patients in Switzerland-Prospective multicentre study. Br Med J 315:1194-1199, 1997
11. Gruber A, Speth C, Lukasser-Vogl E, Zangerle R, Borg-von Zepelin M, Dierich MP, Würzner R: Human immunodefiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 41:227-234, 1999
12. Hoegl L, Thoma-Greber E, Rocken M, Korting HC: Shift from persistent oral pseudomembranous to erythemasous candidosis in a human immunodeficiency virus (HIV)-infected patient upon combination treatment with an HIV protease inhibitor. Mycoses 41:213-217, 1998
13. Hsu A, Granneman GR, Witt G, et al: Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 41:898-905, 1997
14. Johnson GD, Davidson RS, McNamee KC, Russel G, Goodwin D, Holborow EJ: Fading of immunofluorescence during microscopy: a study of the phenomenon and ist remedy. J Immunol Methods 55:231-242, 1982
15. Kaminishi H, Tanaka M, Cho T, Macda H, Hagihara Y: Activation of the plasma kallikrein-kinin system by Candida albicans proteinase. Infect Immunity 58:2139-2143, 1990
16. Kaminishi H, Hamatake H, Cho T, et al: Activation of blood clotting factors by microbial proteinases. FEMS Microbiol Lett 121:327-332, 1994
17. Ledergerber B, Egger M, Opravil M, et al: for the Swiss HIV Cohort Study: Highly active antiretroviral therapy: low rates of clinical disease progression despite high rates of virological failure. Lancet 353:863-868, 1999
18. Monod M, Togni G, Hube B, Sanglard D: Multiplicity of genes encoding secreted aspartic proteinases in Candida species. Mol Microbiol 13:357-368, 1994
19. Monod M, Hube B, Hess D, Sanglard D: Differential regulation of SAP8 and SAP9 which encode two new members of the secreted aspartic proteinase family in Candida albicans. Microbiology 144:2731-2737, 1998
20. Odds FC: Candida and Candidosis. London: Ballière Tindall, 1988
21. Ollert MW, Söhnchen R, Korting HC, Ollert U, Bräutigam S, Bräutigam W: Mechanisms of adherence of Candida albicans to cultured human epidermal keratinocytes. Infect Immun 61:4560-4568, 1993
22. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodefficiency virus infection. N Engl J Med 338:853-860, 1998
23. Penzak SR, Gubbins PO: Preventing and treating azole-resistant oropharyngeal candidiasis in HIV-infected patients. Am J Health Syst Pharm 55:279-283, 1998
24. Rao JKM, Erickson JW, Wlodawer A: Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. Biochemistry 30:4663-4671, 1990
25. Rüchel R: On the renin like activity of Candida proteinase and activation of blood coagulation in vitro. Zeitschr Bakteriol Hyg A 255:368-379, 1983
26. Schaller M, Schäfer W, Korting HC, Hube B: Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol 29:605-615, 1998